BioSpace News Archive

Scott Thomson has been appointed CEO of SPI Pharma. A highly experienced international business executive with a proven track record in strategy development and execution, operational management, and innovation for Specialty Ingredients, Scott joins SPI Pharma after 29 years with BASF.

CrossBay Medical, Inc., a health technology company focused on improving the delivery of women’s healthcare, announced it has received clearance from the Food and Drug Administration (FDA) to market its CrossGlide™ ETS Plus. Similar to the CrossGlide ETS, Endometrial Tissue Sampler (which received FDA clearance this summer), the ETS Plus also enables medical providers to perform a frictionless, office-based endometr

VEO Diagnostics announces the launch and sole distribution rights in the United States to the ACCEL ELISA ® COVID-19 kit, a serological microplate-based enzyme linked immunosorbent assay (ELISA) for the qualitative detection of total antibodies (includi

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has finalized its settlement with the U.S. Department of Justice and the U.S. Department of Health and Human Services. In order to avoid distraction from its core mi

LTC ACO, the first long-term care sponsored Accountable Care Organization (“ACO”) in the United States and a subsidiary of Genesis HealthCare (Genesis) (NYSE:GEN), recently received a positive reconciliation and settlement under the Medicare Shared Savings Program (“MSSP”) for the 2019 performance year and as a result, generated shared savings for the second consecutive year. During 2019, the Company managed approximately 5,800 Medicare

Mirum Pharmaceuticals, Inc. announced that on October 9, 2020, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,100 shares of common stock to seven new employees under Mirum’s 2020 Inducement Plan.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20, 2020 at 9:30 a.m. ET. A live audio webcast of the even

Kadmon Holdings, Inc. announced that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market.

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced publication of data in a murine model of GM1 gangliosidosis (GM1) demonstrating that a single intracerebroventricular injection of an optimized adeno-associated virus (AAV) into the cerebral spinal fluid (CSF) resulted in significant expression of Beta-galactosidase (β-g

Codiak BioSciences, Inc., a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of approximately $82.5 million, before deducting underwriting discounts and commissions and offering expenses.